172 Results

People

  1. Motzer
    Motzer
  2. Abrey
    Abrey
  3. De Angelis
    De Angelis
  4. Riely
    Riely
  5. Abou-Alfa
    Abou-Alfa
  6. Kelly
    Kelly
  7. Scher
    Scher
  8. Drilon
    Drilon
  9. Feldman
    Feldman
  10. Ginsberg
    Ginsberg

Groups

  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)
  7. Biostatistics Service (27)
  8. Thoracic Oncology (19)
  9. Division of Subspecialty Medicine (18)
  10. GSK Faculty (18)
  1. "hypophosphatemia"
Formats
  1. Journal Article (160)
  2. Review (7)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)

More Groups

People
  1. Robert Motzer (18)
  2. Lauren Abrey (9)
  3. Lisa De Angelis (8)
  4. Gregory Riely (7)
  5. Ghassan Abou-Alfa (6)
  6. Howard Scher (6)

More People

Years
  1. 2025 (8)
  2. 2024 (13)
  3. 2023 (13)
  4. 2022 (7)
  5. 2021 (4)
  6. 2020 (21)

More Years

Publications
  1. Lancet Oncology (16)
  2. Cancer (11)
  3. Clinical Cancer Research (11)
  4. Journal of Clinical Oncology (10)
  5. New England Journal of Medicine (10)
  6. Neuro-Oncology (6)

More Publications

Publishers
  1. Elsevier Science, Inc. (25)
  2. Elsevier Inc. (19)
  3. American Association for Cancer Research (12)
  4. Wiley Blackwell (12)
  5. Oxford University Press (11)
  6. Springer (11)

More Publishers

Results (172)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
    Journal Article

    Wudhikarn, K.; Pennisi, M.; Garcia-Recio, M.; Flynn, J. R.; Afuye, A.; Silverberg, M. L.; Maloy, M. A.; Devlin, S. M.; Batlevi, C. L.; Shah, G. L.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Consensus recommendations for management and counseling of adverse events associated with lorlatinib: A guide for healthcare practitioners
    Guidelines

    Reed, M.; Rosales, A. L. S.; Chioda, M. D.; Parker, L.; Devgan, G.; Kettle, J.
    Advances in Therapy (2020)

    Fulltext@MSK | Save
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
    Journal Article

    Goldberg, A. D.; Atallah, E.; Rizzieri, D.; Walter, R. B.; Chung, K. Y.; Spira, A.; Stock, W.; Tallman, M. S.; Cruz, H. G.; Boni, J.; more...
    Leukemia Research (2020)

    Fulltext@MSK | Save
  • Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study
    Journal Article

    Abou-Alfa, G. K.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
    Journal Article

    O'Reilly, E. M.; Barone, D.; Mahalingam, D.; Bekaii-Saab, T.; Shao, S. H.; Wolf, J.; Rosano, M.; Krause, S.; Richards, D. A.; Yu, K. H.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
    Journal Article

    Schroeder, M. A.; Jean Khoury, H.; Jagasia, M.; Ali, H.; Schiller, G. J.; Staser, K.; Choi, J.; Gehrs, L.; Arbushites, M. C.; Yan, Y.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia
    Journal Article

    Shah, N. N.; Bhojwani, D.; August, K.; Baruchel, A.; Bertrand, Y.; Boklan, J.; Dalla-Pozza, L.; Dennis, R.; Hijiya, N.; Locatelli, F.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials
    Journal Article

    Hong, D. S.; DuBois, S. G.; Kummar, S.; Farago, A. F.; Albert, C. M.; Rohrberg, K. S.; van Tilburg, C. M.; Nagasubramanian, R.; Berlin, J. D.; Federman, N.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Renal toxicity of systemic therapy for renal cell carcinoma
    Review

    Jaimes, E. A.
    Seminars in Nephrology (2020)

    Fulltext@MSK | Save
  • Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Journal Article

    Shapiro, G. I.; LoRusso, P.; Kwak, E.; Pandya, S.; Rudin, C. M.; Kurkjian, C.; Cleary, J. M.; Pilat, M. J.; Jones, S.; de Crespigny, A.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save